HDM1002 (Sovleplenib)
Primary Immune Thrombocytopenia (ITP)
Key Facts
About Huadong Medicine (HD Medicine)
Huadong Medicine's mission is to become a global leader in pharmaceutical innovation, improving human health through the discovery and delivery of high-quality medicines. The company has achieved significant scale as one of China's largest and most valuable publicly traded pharma firms, with a robust commercial portfolio and a maturing R&D pipeline. Its strategy hinges on a dual approach: deepening its presence in the massive domestic market through commercialization and partnerships, while advancing a proprietary pipeline of novel biologics and small molecules to compete globally. Sustained high R&D investment and strategic business development are central to this growth plan.
View full company profileAbout Huadong Medicine (HD Medicine)
Huadong Medicine's mission is to become a global leader in pharmaceutical innovation, improving human health through the discovery and delivery of high-quality medicines. The company has achieved significant scale as one of China's largest and most valuable publicly traded pharma firms, with a robust commercial portfolio and a maturing R&D pipeline. Its strategy hinges on a dual approach: deepening its presence in the massive domestic market through commercialization and partnerships, while advancing a proprietary pipeline of novel biologics and small molecules to compete globally. Sustained high R&D investment and strategic business development are central to this growth plan.
View full company profileTherapeutic Areas
Other Primary Immune Thrombocytopenia (ITP) Drugs
| Drug | Company | Phase |
|---|---|---|
| Efgartigimod | Argenx | Approved |
| Sovleplenib (HMPL-523) | HUTCHMED | Phase III |
| Orelabrutinib | Zenas BioPharma | Phase 3 |